Catalyst Pharmaceuticals draws Italian buyer interest as US rare disease assets fetch premium

Catalyst Pharmaceuticals, the US rare-disease drug developer, has emerged as a potential acquisition target for Italy's Angelini Pharma, in the latest sign of how aggressively European drugmakers are scouring the US market for commercial-stage assets in orphan indications.

BofA Securities reiterated its "buy" rating and $35 price target on the Coral Gables, Florida-based group on Monday, after Bloomberg reported that Angelini was reviewing Catalyst alongside other potential deal targets. Discussions are described as preliminary, and Catalyst has not commented on the report. Shares in Catalyst were trading at $29.27, giving the company a market capitalisation of $3.6bn and a price-to-earnings ratio of 17.5.

BofA cast Catalyst as "a potentially attractive target for strategic buyers in the rare orphan space seeking commercial-stage assets with aggregate peak revenue exceeding $1bn", flagging both the durability of the company's underlying franchise and the optionality embedded in its primary product Firdapse, used to treat Lambert-Eaton myasthenic syndrome — a rare neuromuscular disorder.

Firdapse faces a near-term US litigation outcome that will be material to the investment case. BofA models generic entry no earlier than 2035 and argued the risk-reward "skews in Catalyst Pharmaceuticals' favour" assuming a favourable judicial outcome. The broker said upside from such a ruling was not yet reflected in the stock price, citing strong organic growth and what it described as "underappreciated asset durability".

The reported approach lands at a moment of robust commercial momentum for Catalyst. The group beat consensus estimates for the fourth quarter of 2025, posting earnings per share of $0.68 against expectations of $0.31, on revenue of $152.6mn versus a $141.5mn forecast. Firdapse generated $97.6mn in quarterly revenue, an 18 per cent rise on the prior year, while Agamree — a treatment for Duchenne muscular dystrophy — contributed $35.3mn, up 68 per cent year-on-year. Oppenheimer reiterated its "outperform" rating with a $33 price target following the results.

Angelini's interest reflects a broader trend in pharmaceutical M&A. European drugmakers, both publicly listed and privately held, have been increasingly prepared to look across the Atlantic for differentiated rare-disease assets, drawn by the higher pricing power, more permissive regulatory environment for ultra-orphan indications, and the predictable revenue streams typically generated by treatments serving small but well-defined patient populations. Privately held Angelini, controlled by the Angelini family, has been pursuing geographic and therapeutic diversification, with rare diseases and central nervous system disorders identified as priority areas.

For shareholders in Catalyst, the disclosure of preliminary takeover interest creates a familiar dynamic: a clear floor under the share price set by potential strategic value, alongside the prospect of upside should a formal bid materialise — though BofA's $35 target leaves the equity already trading at a discount to its standalone valuation case, before any takeover premium is factored in.